ViabilityEmbryoscopeNCT02081859
Use of Time-lapse Morphological Kinetics in the Selection of Blastocysts
A study testing Embryoscope and Conventional Criteria in people with Viability, run by The Cleveland Clinic at 1 site in United States.
Trial summary
This is a randomized controlled observational trial to determine if data obtained from the embryoscope is helpful in determining which blastocysts to transfer. Read more about this study
- Who is it for?
- Ages 18 to 45 years, women only
- Conditions the study is for
- Viability
- What is being tested?
- Embryoscope and Conventional Criteria
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 300 participants
- Where
- 1 siteUnited States
- Study dates
- Apr 2014to Jan 2016
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Patients undergoing an IVF cycle between the age of 18-45 at the Cleveland Clinic Reproductive Endocrinology and Infertility clinic with the plan for transfer of embryo(s) will be offered the opportunity to participate in this study.
Who cannot join
- The only patients excluded will be those undergoing pre-implantation genetic testing and/or chromosome screening.
Trial locations and contacts
1 site in 1 country.
United States1 site
Cleveland Clinic Beachwood Family Health Center
Beachwood, Ohio, 44122
About this study
Official title: Does Use of Time-lapse Morphological Kinetics in the Selection of Blastocysts for Transfer Improve Pregnancy Rates?
This is a randomized controlled observational trial to determine if data obtained from the embryoscope is helpful in determining which blastocysts to transfer.
Read the detailed description
Materials and Methods:
Patient Selection:
Patients undergoing an IVF cycle at the Cleveland Clinic Reproductive Endocrinology and Infertility clinic with the plan for transfer of embryo(s) will be offered the opportunity to participate in this study. We would like a total enrollment 300 patients with 150 in each group. The only patients excluded will be those undergoing pre-implantation genetic testing and/or chromosome screening.
Study Design This will be a prospective randomized controlled trial where all patients who agree to participate will be randomized to having embryo selection for transfer based solely on conventional criteria or alternatively conventional criteria in conjunction with morphokinetic criteria.
Enrollment:
Patients will be enrolled at the Beachwood IVF center by the REI physicians at the time of the IVF consultation. They will sign the informed consent for the study at the time that they sign the consent for IVF treatment, which is done by the IVF nurses. Informed consent for the study will be kept in the patient chart in the Beachwood IVF center along with the IVF consent.
Randomization:
Patients will be randomized 1:1 to Conventional embryo selection vs. Embryoscope selection using a computer generated random number sequence. Group assignment will be written on a piece of paper and placed in consecutively numbered opaque envelopes by research personnel not involved in embryo selection. Each patient randomized will be assigned the next consecutive number and the embryo selection criteria will be revealed at time of oocyte retrieval. Patients, REI physicians and staff, and sonographers will be blinded as to how embryos are selected. Only the embryologist and the lab staff will be aware of which group the patients are randomized into. This will be ensured by not placing the group in the computerized medical record or the clinical chart, but only in the laboratory chart and the research database.
Sample Size Justification Little published data is available on time-lapse imaging and human embryo selection for transfer. No publications of randomized controlled trials are available on the EmbryoScope. Statistician Benjamin Nutter was consulted for sample size estimation. Initially, based on the 2012 outcomes there was a pregnancy rate of 49%. For a power of 80%, in order to detect an increase to 55% pregnancy rates under the new selection guidelines, we would need to randomize 1088 patients. To see an increase to 60% pregnancy rates, we would need to randomize 320 patients.
In this study, we will be focusing on those patients who have blastocysts available for transfer since blastocysts are the embryos that we need the most assistance with selection. The pregnancy rate in this subset of patients is currently 70% and to detect an increase to 80% would require randomization of 231 patients. Based on these numbers we feel it is reasonable to start with a goal of 300 patients in this study as there will be some patients that do not make it to retrieval, some that have no fertilization and some that have no embryos progress to transfer. Starting with a goal of 300 patients will hopefully give us a large enough sampling to do a preliminary analysis of embryos resulting in a clinically evident pregnancy as defined by positive fetal heart rate.
Given that the outcome of this study is pregnancy rate we will assess the data collected after six months to evaluate if there is a clear difference between groups. If there is a significant difference at that time, the study may be terminated to allow for all patients to have the benefit of the superior method.
Research Procedure The basic IVF laboratory protocols utilized will be the same as that used for all patients. Oocytes will be recovered by transvaginal aspiration of follicles under ultrasound guidance. Oocytes will be inseminated by intracytoplasmic sperm injection or co-incubation with sperm. The next morning, normally fertilized oocytes will be identified and moved to individual wells in a slide chamber and placed in the EmbryoScope.
Those randomized to classic evaluation will have their embryos graded based on conventional daily evaluation at specified daily time points. These criteria encompass timely development to specific benchmarks at 20, 26, 44, 68, 92, 116 and 140 hours post-insemination.
The images will be from the EmbryoScope, but will be static in time and will not span across a time range. Embryos will be graded and selected for transfer according to the laboratory's conventional criteria. Those randomized to classic evaluation plus morphokinetic parameters will have embryo evaluation performed at the same defined intervals but using the data analysis software and the captured time-lapse images to include timing of mitotic intervals, cleavage planes, timing of compaction and cavitation in embryos leading to blastocyst formation.
Patients electing not to participate in the study would still have their embryos cultured in the EmbryoScope and conventional embryo selection criteria would be applied to identify embryos fro transfer.
- Conditions
- Viability
- Being tested
- Embryoscope, Conventional Criteria
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EmbryoscopeDevice
The embryoscope is a microscope that allows for continuous time-lapse monitoring.
Conventional CriteriaOther
| Study group | Role | What they receive |
|---|---|---|
| Conventional grading | Placebo comparator | Embryos will be scored based on conventional criteria. Receives: Other: Conventional Criteria |
| Embryoscope data | Active comparator | Embryos will be scored based on both conventional rating and embryoscope data. Receives: Device: Embryoscope |
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinical Pregnancy Rate
Patients will have a ultrasound to document fetal heart rate approximately 6 weeks after start of IVF cycle.
Measured: 6 weeks
Secondary outcomes (1)
Implantation Rate
Percent of embryos implanted assessed at time of ultrasound
Measured: 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Mar 2014 (estimated)
- Study startApr 2014
- Primary completionJan 2016
- Study completionJan 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for ViabilityStudies of the same condition, open and under way.
- More trials run by The Cleveland ClinicThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 300 participants (actual)
Sponsor and investigators
- Lead sponsor
- The Cleveland Clinic
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Nina Desai, PhD, Principal investigator, The Cleveland Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02081859
- Sponsor's protocol ID
- 14-090
- Acronym
- Embryoscope
- Status last verified
- May 2017
- First submitted
- 5 Mar 2014
- Last updated
- 8 Jun 2017
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Goodman LR, Goldberg J, Falcone T, Austin C, Desai N. Does the addition of time-lapse morphokinetics in the selection of embryos for transfer improve pregnancy rates? A randomized controlled trial. Fertil Steril. 2016 Feb;105(2):275-85.e10. doi: 10.1016/j.fertnstert.2015.10.013. Epub 2015 Oct 29.
PubMed 26522611
Study at a glance
From the registry record, last updated by the sponsor on 8 Jun 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Does Use of Time-lapse Morphological Kinetics in the Selection of Blastocysts for Transfer Improve Pregnancy Rates?
- ClinicalTrials.gov ID
- NCT02081859
- Acronym / sponsor ID
- Embryoscope / 14-090
- Conditions
- Viability
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 300 participants (actual)
- Lead sponsor
- The Cleveland ClinicUniversity, hospital or other
- Study start
- Apr 2014
- Primary completion
- Jan 2016 (actual)
- Study completion
- Jan 2016 (actual)
- First posted
- 7 Mar 2014 (estimated)
- Results
- Posted 15 May 2017
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a randomized controlled observational trial to determine if data obtained from the embryoscope is helpful in determining which blastocysts to transfer.
Detailed description
Materials and Methods:
Patient Selection:
Patients undergoing an IVF cycle at the Cleveland Clinic Reproductive Endocrinology and Infertility clinic with the plan for transfer of embryo(s) will be offered the opportunity to participate in this study. We would like a total enrollment 300 patients with 150 in each group. The only patients excluded will be those undergoing pre-implantation genetic testing and/or chromosome screening.
Study Design This will be a prospective randomized controlled trial where all patients who agree to participate will be randomized to having embryo selection for transfer based solely on conventional criteria or alternatively conventional criteria in conjunction with morphokinetic criteria.
Enrollment:
Patients will be enrolled at the Beachwood IVF center by the REI physicians at the time of the IVF consultation. They will sign the informed consent for the study at the time that they sign the consent for IVF treatment, which is done by the IVF nurses. Informed consent for the study will be kept in the patient chart in the Beachwood IVF center along with the IVF consent.
Randomization:
Patients will be randomized 1:1 to Conventional embryo selection vs. Embryoscope selection using a computer generated random number sequence. Group assignment will be written on a piece of paper and placed in consecutively numbered opaque envelopes by research personnel not involved in embryo selection. Each patient randomized will be assigned the next consecutive number and the embryo selection criteria will be revealed at time of oocyte retrieval. Patients, REI physicians and staff, and sonographers will be blinded as to how embryos are selected. Only the embryologist and the lab staff will be aware of which group the patients are randomized into. This will be ensured by not placing the group in the computerized medical record or the clinical chart, but only in the laboratory chart and the research database.
Sample Size Justification Little published data is available on time-lapse imaging and human embryo selection for transfer. No publications of randomized controlled trials are available on the EmbryoScope. Statistician Benjamin Nutter was consulted for sample size estimation. Initially, based on the 2012 outcomes there was a pregnancy rate of 49%. For a power of 80%, in order to detect an increase to 55% pregnancy rates under the new selection guidelines, we would need to randomize 1088 patients. To see an increase to 60% pregnancy rates, we would need to randomize 320 patients.
In this study, we will be focusing on those patients who have blastocysts available for transfer since blastocysts are the embryos that we need the most assistance with selection. The pregnancy rate in this subset of patients is currently 70% and to detect an increase to 80% would require randomization of 231 patients. Based on these numbers we feel it is reasonable to start with a goal of 300 patients in this study as there will be some patients that do not make it to retrieval, some that have no fertilization and some that have no embryos progress to transfer. Starting with a goal of 300 patients will hopefully give us a large enough sampling to do a preliminary analysis of embryos resulting in a clinically evident pregnancy as defined by positive fetal heart rate.
Given that the outcome of this study is pregnancy rate we will assess the data collected after six months to evaluate if there is a clear difference between groups. If there is a significant difference at that time, the study may be terminated to allow for all patients to have the benefit of the superior method.
Research Procedure The basic IVF laboratory protocols utilized will be the same as that used for all patients. Oocytes will be recovered by transvaginal aspiration of follicles under ultrasound guidance. Oocytes will be inseminated by intracytoplasmic sperm injection or co-incubation with sperm. The next morning, normally fertilized oocytes will be identified and moved to individual wells in a slide chamber and placed in the EmbryoScope.
Those randomized to classic evaluation will have their embryos graded based on conventional daily evaluation at specified daily time points. These criteria encompass timely development to specific benchmarks at 20, 26, 44, 68, 92, 116 and 140 hours post-insemination.
The images will be from the EmbryoScope, but will be static in time and will not span across a time range. Embryos will be graded and selected for transfer according to the laboratory's conventional criteria. Those randomized to classic evaluation plus morphokinetic parameters will have embryo evaluation performed at the same defined intervals but using the data analysis software and the captured time-lapse images to include timing of mitotic intervals, cleavage planes, timing of compaction and cavitation in embryos leading to blastocyst formation.
Patients electing not to participate in the study would still have their embryos cultured in the EmbryoScope and conventional embryo selection criteria would be applied to identify embryos fro transfer.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Conventional grading | Placebo comparator | Other: Conventional CriteriaEmbryos will be scored based on conventional criteria. |
| Embryoscope data | Active comparator | Device: EmbryoscopeEmbryos will be scored based on both conventional rating and embryoscope data. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Patients undergoing an IVF cycle between the age of 18-45 at the Cleveland Clinic Reproductive Endocrinology and Infertility clinic with the plan for transfer of embryo(s) will be offered the opportunity to participate in this study.
Key exclusion criteria (1 listed)
- The only patients excluded will be those undergoing pre-implantation genetic testing and/or chromosome screening.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EmbryoscopeThe embryoscope is a microscope that allows for continuous time-lapse monitoring. | Device | Embryoscope data |
| Conventional Criteria | Other | Conventional grading |
Primary outcome
Clinical Pregnancy Rate
Time frame: 6 weeks
Patients will have a ultrasound to document fetal heart rate approximately 6 weeks after start of IVF cycle.
1 secondary outcome
Implantation Rate
Time frame: 6 weeks
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jun 2017.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 26522611Goodman LR, Goldberg J, Falcone T, Austin C, Desai N. Does the addition of time-lapse morphokinetics in the selection of embryos for transfer improve pregnancy rates? A randomized controlled trial. Fertil Steril. 2016 Feb;105(2):275-85.e10. doi: 10.1016/j.fertnstert.2015.10.013. Epub 2015 Oct 29.
Related trials for Viability
Not yet recruiting
New Biomarkers for Organ Viability Assessment During Hypothermic Machine Perfusion in Liver Transplantation: the Role of Extemporaneous Histological Examination.
Liver Transplantation (LT), Early Allograft Dysfunction
Recruiting
To Investigate the Feasibility and Acceptability of Trained Non-medical Professionals Performing Laser Treatment for Proliferative Diabetic Retinopathy (PDR), and the Potential Impact on Service Capacity. Assess Feasibility of Conducting a Full Trial Comparing Trained ECPs With Ophthalmologists
Proliferative Diabetic Retinopathy (PDR)
Not yet recruiting
Laser-Activated Versus Passive Ultrasonic Irrigation in Endodontic Retreatment
Apical Periodontitis
Recruiting
Randomized Study of a Dematerialized Management for Post-Emergency Gynecological Follow-Up
Genital Diseases, Female, Ectopic Pregnancy
Not yet recruitingPhase 4
Effectiveness of Pre-Procedural CPC and Zinc Mouthwash in Reducing Dental Aerosols
Bacterial Contamination
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nina Desai, PhD principal investigator
The Cleveland Clinic
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Embryoscope and Conventional Criteria in people with Viability, run by The Cleveland Clinic at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Jun 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 15 May 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Clinical Pregnancy Rate (time frame: 6 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02081859, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jun 2017.